8-K: Quanterix Announces Q1 2025 Financial Results and Cost Reduction Plan

Quanterix reports a 5% revenue decrease in Q1 2025, implements a cost reduction plan, and advances its merger with Akoya Biosciences.

Summary

• Quanterix Corporation announced its financial results for the first quarter ended March 31, 2025.
• Revenue for the quarter was $30.3 million, a 5% decrease compared to $32.1 million in the prior year.
• GAAP gross margin was 54.1%, compared to 57.8% in the prior year.
• The company reported a net loss of $20.5 million, compared to a net loss of $11.2 million in the prior year.
• Quanterix ended the quarter with $269.5 million in cash, cash equivalents, marketable securities, and restricted cash.
• The company is implementing cost reduction initiatives to achieve $30 million in annual savings.
• Quanterix expects 2025 revenues to be in the range of $120 million to $130 million, a year-over-year decline of 5% to 13%.
• The company anticipates 2025 adjusted cash burn to be approximately $35.0 million to $45.0 million.
• The merger agreement with Akoya Biosciences was amended, reducing the equity value of the transaction by 67% and increasing Quanterix shareholder ownership from 70% to 84% post-closing; the transaction is expected to close in June 2025.
• A new early-access program will make Simoa ONE assay kits compatible with over 20,000 existing flow cytometers worldwide.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is taking proactive steps to reduce costs and streamline operations, the Q1 results show a decline in revenue and an increased net loss. The amended merger agreement and expansion of Simoa ONE are positive developments, but the overall outlook is tempered by market headwinds.

Positives

• Quanterix is implementing cost reduction initiatives expected to save $30 million annually.
• The company is proactively positioning itself for long-term success and aims to generate positive cash flow by 2026.
• The merger agreement with Akoya Biosciences was amended, increasing Quanterix shareholder ownership to 84% post-closing.
• ARUP Laboratories will offer a pTau217 blood test for Alzheimer's disease using the Quanterix platform.
• Simoa ONE assay kits will become compatible with over 20,000 existing flow cytometers worldwide, expanding access to ultrasensitive biomarker detection.

Negatives

• Quanterix's Q1 2025 revenue decreased by 5% year-over-year.
• The company reported a net loss of $20.5 million for Q1 2025, compared to a net loss of $11.2 million in the prior year.
• The company expects a revenue decline of 5% to 13% for the full year 2025.
• GAAP gross margin decreased from 57.8% to 54.1%.

Risks

• The company faces risks related to the impact of recent U.S. government policies, including reductions in federal research funding and increased tariffs.
• There is a risk that Quanterix may not realize the expected benefits of its cost reduction actions.
• The company faces risks associated with the anticipated timing for launch of, and features of, Quanterixs next-generation instrument, Simoa ONE.
• Quanterix may fail to realize the anticipated benefits and synergies of its recent acquisition of Emission, Inc.
• The company's estimates regarding expenses, future revenues, capital requirements, and needs for additional financing could be incorrect.
• There are risks related to the restatement of Quanterixs consolidated financial statements, including risks of increased costs and the increased possibility of legal proceedings and regulatory inquiries, sanctions, or investigation.
• Quanterix faces risks related to its ability to maintain effective internal control over financial reporting and disclosure controls and procedures, including its ability to remediate existing material weaknesses in its internal control over financial reporting and the timing of any such remediation.
• The company's ability to realize the intended benefits of its assay redevelopment program is a risk.
• Quanterix's ability to retain and expand its customer base and achieve sufficient market acceptance of its products is a risk.
• The merger with Akoya Biosciences carries risks, including the possibility of termination, failure to obtain necessary approvals, failure to realize anticipated benefits and synergies, increased expenses, diversion of management's attention, and potential adverse reactions or changes to business or employee relationships.

Future Outlook

Quanterix anticipates achieving positive cash flow by 2026 and expects 2025 revenues to be in the range of $120 million to $130 million, with an adjusted cash burn of $35 million to $45 million.

Management Comments

• Masoud Toloue, CEO of Quanterix, stated that the company remains committed to keeping the innovation engine moving forward despite market resource constraints.
• Toloue highlighted the new early-access program for Simoa ONE assay kits, making them compatible with existing flow cytometers.
• Toloue mentioned that the company is proactively positioning itself for long-term success and implementing targeted cost reductions of approximately $30 million annually.
• Toloue noted that these actions strengthen the path to generate positive cash flow by 2026 and help streamline the integration with Akoya Biosciences.

Industry Context

Quanterix is operating in a market facing resource constraints and headwinds, including cuts to academic research funding, biopharma spending patterns, and tariffs; the company is adapting by reducing costs and expanding the reach of its technology.

Comparison to Industry Standards

• The company's revenue decline reflects broader challenges in the life sciences industry, where funding cuts and economic uncertainty are impacting growth.
• The cost reduction plan aligns with industry trends as companies seek to improve efficiency and profitability in a challenging environment.
• The expansion of Simoa ONE assay kit compatibility with existing flow cytometers positions Quanterix to compete more effectively with companies like Luminex and Bio-Rad, which have a large installed base of instruments.
• The amended merger agreement with Akoya Biosciences reflects a strategic move to consolidate and strengthen its position in the biomarker analysis market, similar to other mergers and acquisitions in the diagnostics space.

Stakeholder Impact

• Shareholders will be impacted by the amended merger agreement with Akoya Biosciences, which increases Quanterix shareholder ownership but reduces the equity value of the transaction.
• Employees will be affected by the cost reduction plan, which includes headcount reductions.
• Customers will benefit from the expanded access to Simoa technology through the new early-access program and the launch of new products and services.
• Suppliers may be impacted by the cost reduction plan, which includes a reduction in other costs.

Next Steps

• Complete the merger with Akoya Biosciences, expected to close in June 2025.
• Implement cost reduction initiatives to achieve $30 million in annual savings.
• Launch the new early-access program for Simoa ONE assay kits.
• Continue to develop and commercialize new products and services, such as the pTau217 blood test and the dried blood spot extraction kit.

Key Dates

Keywords

Quanterix, financial results, Q1 2025, cost reduction, Akoya Biosciences, merger, revenue, gross margin, net loss, cash burn, Simoa, biomarker detection